Skip to main content
. 2021 Jul 1;2(8):100205. doi: 10.1016/j.jtocrr.2021.100205

Figure 3.

Figure 3

Progression-free survival in patients with a PD-L1 TPS of ≥50% in patients (A) with and (B) without baseline brain metastases and in patients with a PD-L1 TPS of ≥1% in patients (C) with and (D) without baseline brain metastases. The response was assessed per Response Evaluation Criteria in Solid Tumors version 1.1 by blinded, independent central review. Four patients in the pooled intent-to-treat population had missing progression-free survival data. CI, confidence interval; HR, hazard ratio; PD-L1, programmed death-ligand 1; TPS, tumor proportion score.